Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Hepatitis C virus antigen-antibody joint detection method and kit

A hepatitis C virus, antigen antibody technology, applied in the field of immune detection, can solve the problems of detection sensitivity reduction, achieve the effects of improving detection sensitivity, reducing interference of low-affinity antibodies, and low detection cost

Pending Publication Date: 2020-08-11
CHEMCLIN DIAGNOSTICS CO LTD
View PDF8 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, once HCV-infected patients produce antibodies in vivo and undergo seroconversion, antigen-antibody complexes can be formed between anti-core antigen antibodies and HCVcAg, and the detection sensitivity will be significantly reduced

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Hepatitis C virus antigen-antibody joint detection method and kit
  • Hepatitis C virus antigen-antibody joint detection method and kit
  • Hepatitis C virus antigen-antibody joint detection method and kit

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0108] Example 1: Preparation of receptor-HCV antibody 1 (for the N-terminal epitope of HCV core antigen)

[0109] 1) Antibody treatment: HCV antibody 1 was dialyzed, replaced with coating buffer, and the protein concentration was measured.

[0110] 2) Receptor treatment: replace the receptor with coating buffer through centrifugation, ultrasound and other processes;

[0111] 3) Coupling: The treated receptor and the treated HCV antibody 1 are mixed and reacted, and after reduction and blocking processes, the receptor-HCV antibody 1 is obtained, and the volume is fixed and stored in a preservation solution.

Embodiment 2

[0112] Example 2: Preparation of biotin-HCV antibody 2 (for the C-terminal epitope of HCV core antigen)

[0113]1) Antibody treatment: HCV antibody 2 was dialyzed, replaced with labeling buffer, and the protein concentration was determined.

[0114] 2) Labeling reaction: the treated HCV antibody 2 is mixed with activated biotin for labeling.

[0115] 3) Dialysis: Dialyze the labeled biotin-HCV antibody 2 to remove unlabeled free biotin.

[0116] 4) Preservation: The protein concentration of the dialyzed biotin-HCV antibody 2 was measured, and stored after adding glycerol.

Embodiment 3

[0117] Example 3: Preparation of receptor-HCV antigen 1

[0118] 1) Antigen treatment: HCV antigen 1 was dialyzed, replaced with coating buffer, and the protein concentration was measured.

[0119] 2) Receptor treatment: replace the receptor with coating buffer through centrifugation, ultrasound and other processes;

[0120] 3) Coupling: The processed receptor and the processed HCV antigen 1 are mixed and reacted, and after reduction and blocking processes, the receptor-HCV antigen 1 is obtained, and the volume is fixed and stored in a preservation solution.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a hepatitis C virus antigen-antibody joint detection method in the technical field of immunodetection. The kit comprises at least two detection areas, whether a first compoundformed by a donor-hepatitis C virus antibody-receptor exists or not is detected in one detection area, and whether a second compound formed by a donor-hepatitis C virus antigen-receptor exists or notis detected in the other detection area, a donor can generate active oxygen in an excited state, and a receptor can react with the active oxygen to generate a detectable chemiluminescence signal. Themethod is advantaged in that the HCV core antigen and the antibody are jointly detected, so detection accuracy is improved, detection cost is low, moreover, a treating agent is added into a core antigen detection hole, so interference of a low-affinity antibody in an early body is reduced, the antigen detection sensitivity in a conversion period is improved, and the HCV detection sensitivity is further improved.

Description

technical field [0001] The invention belongs to the technical field of immunodetection, and in particular relates to a combined detection method and kit for hepatitis C virus antigen and antibody. Background technique [0002] At present, the commonly used hepatitis C virus (HCV) detection kits in China are antibody detection kits. Although the sensitivity and specificity of HCV antibody detection technology are already high, there is still a period of time before the anti-HCV antibody is produced after HCV infection. A longer period of about 40 to 70 days (average 66 days) is called the window period before seroconversion after infection. At this time, HCV antibody detection kits cannot detect it. [0003] HCV core antigen is a marker of early infection in HCV-infected persons. However, once HCV-infected persons produce antibodies in vivo and undergo seroconversion, antigen-antibody complexes can be formed between anti-core antigen antibodies and HCVcAg, and the detection ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/569G01N33/543
CPCG01N33/5767G01N33/54313G01N33/56983
Inventor 吴晨赵琪张林钰李临
Owner CHEMCLIN DIAGNOSTICS CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com